The Aragonese vaccine against tuberculosis could be effective against bladder cancer
The live attenuated vaccine against tuberculosis Mtvbac, built at the University of Zaragoza and developed by the Galician company Biofabri belonging to the Zendal group, and which is soon expected to begin phase III efficacy studies in babies in South Africa, could have applications to treat diseases beyond tuberculosis. This is the case of non-muscle …
The Aragonese vaccine against tuberculosis could be effective against bladder cancer Read More »